Overview

Open Label Extension of TUDCA-ALS Study

Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This study will provide extended access to patients and assess longer-term outcomes on patients who have completed the TUDCA-ALS study.
Phase:
Phase 3
Details
Lead Sponsor:
Humanitas Mirasole SpA
Collaborators:
Bruschettini S.r.l.
Istituto Superiore di Sanità
KU Leuven
Motor Neurone Disease Association
UMC Utrecht
University Hospital, Tours
University of Dublin, Trinity College
University of Sheffield
University of Ulm
Treatments:
Ursodoxicoltaurine